Aradigm Corporation  

(Public, NASDAQ:ARDM)   Watch this stock  
Find more results for OTC:ARDM
+0.07 (1.61%)
May 6 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.40 - 4.68
52 week 2.60 - 7.90
Open 4.40
Vol / Avg. 4,360.00/13,490.00
Mkt cap 63.49M
P/E     -
Div/yield     -
EPS -1.17
Shares 14.76M
Beta 0.94
Inst. own 46%
May 9, 2016
Q1 2016 Aradigm Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 15, 2016
Q4 2015 Aradigm Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -26720.00% -73.45%
Operating margin -26688.57% -73.21%
EBITD margin - -72.30%
Return on average assets -93.23% -38.42%
Return on average equity -135.94% -55.31%
Employees 16 -
CDP Score - -


3929 Point Eden Way
HAYWARD, CA 94545-3720
United States - Map
+1-510-2659000 (Phone)
+1-510-2658878 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aradigm Corporation is a pharmaceutical company. The Company is focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin, which is in Phase III clinical trials. The Company also invested on AERx pulmonary drug delivery platform and other technologies. The Company's partnered programs under development include Inhaled Ciprofloxacin. The Company is also developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine) program. Its lead development candidates are the Company's formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF).

Officers and directors

Virgil D. Thompson J.D. Independent Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
Igor Gonda Ph.D. President, Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Nancy E. Pecota Chief Financial Officer, Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Robert A. Reed Ph.D. Vice President - Regulatory (CMC) and Quality
Bio & Compensation  - Reuters
Juergen Froehlich M.D. Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
David Bell Director
Age: 60
Bio & Compensation  - Reuters
Frederick M. Hudson CPA Independent Director
Age: 69
Bio & Compensation  - Reuters
John M. Siebert Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters